Abstract:

Objective To evaluate the efficacy of Genechip technology in detection of multidrug-resistant tuberculosis (MDR-TB) bacilli, and to explore its clinical value in diagnosis of MDR-TB. Methods From June 1st 2019 to December 31st 2019, smear positive sputum samples of 295 patients in the Fourth Hospital of Inner Mongolia Autonomous Region were continuously enrolled and tested by Genechip. 60 cases for which traditional culture results were failure/contamination/non-tuberculous Mycobacteria, or gene chip couldn’t detect Mycobacterium tuberculosis bacteria or only detected non-tuberculous Mycobacteria were excluded. The susceptibility, specificity, positive predictive value (PPV) and negative predictive value (NPV) of detecting Rifampicin-resistant, Isoniazid-resistant and MDR TB were analyzed by using L-J solid proportion method as standard reference. Results The result indicated that susceptibility, specificity, PPV and NPV of detecting Rifampicin-resistance in 235 patients were 95.7% (22/23), 98.6% (209/212), 88.0% (22/25), 99.5% (209/210), respectively. The susceptibility, specificity, PPV and NPV for detecting Isoniazid-resistance were 80.0% (16/20),98.6% (212/215),84.2% (16/19) and 98.1% (212/216),respectively. The susceptibility, specificity, PPV and NPV for Multi-drug resistance were 76.2% (16/21), 97.2% (208/214), 72.7% (16/22), 97.7% (208/213) and 95.3% (224/235), respectively. Conclusion Using Genechip to detect drug resistantt TB in sputum samplesis of high value,high authenticity and high reliability in the diagnosis of Rifampicin, Isoniazid and Multidrug-resistant tuberculosis.

Key words: Tuberculosis,pulmonary, Tuberculosis,multidrug-resistant, Microbial sensitivity tests, Microchip analytical procedures, Rifampin, Isoniazid, Comparative study